about us
Shanghai Pharma Biotherapeutics USA Inc. (SPHBio) is a wholly-owned subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd. (SPH:http://www.sphchina.com/index/), one of the largest pharmaceutical companies in China.
SPH is a vertically-integrated and diversified pharmaceutical group. The company has dual listings on the stock exchanges in Shanghai (601607) and Hong Kong (02067), respectively. The company provides leading healthcare services in: Research & Development; Manufacturing; Distribution; and, Retail. SPH has developed and delivered healthcare solutions and effective medicines to patients in China for the past century. SPH is committed to continuously bringing innovative medicines to patients that alleviate or cure diseases.
- Attributes:
- • $23B Operating Revenue (2018)
- • Dual listing on Shanghai (601607) and Hong Kong (02067) stock exchanges
- • > 47,000 employees
- • > 700 Products (646 in National Reimbursement Drug List)
- • 50 cGMP-certified manufacturing facilities
- • $200M invested annually in R&D (focus on CNS, Digestive & Metabolic, ImmuneSystem, Oncology, Cerebral & Cerebrovascular)
- • Distribution to > 30,000 Medical Institutions in China
- • > 2,000 Retail pharmacies in China
Our Mission
and investors to identify and advance biopharmaceutical innovations
that address unmet medical needs. Our goals are to:
Identify and acquire Chinese rights to novel therapeutics, serving as the liaison between our partners and SPH to initiate clinical testing and registration in China.
Develop novel SPH therapeutics in the US and identify potential partners.
Conduct cutting-edge R & D to identify novel therapeutics in our research laboratories.
